C2-symmetric inhibitors of Plasmodium falciparum plasmepsin II: synthesis and theoretical predictions. 2003

Karolina Ersmark, and Isabella Feierberg, and Sinisa Bjelic, and Johan Hultén, and Bertil Samuelsson, and Johan Aqvist, and Anders Hallberg
Department of Medicinal Chemistry, Uppsala University, BMC, Box 574, SE-751 23, Uppsala, Sweden.

A series of C(2)-symmetric compounds with a mannitol-based scaffold has been investigated, both theoretically and experimentally, as Plm II inhibitors. Four different stereoisomers with either benzyloxy or allyloxy P1/P1' side chains were studied. Computational ranking of the binding affinities of the eight compounds was carried out using the linear interaction energy (LIE) method relying on a complex previously determined by crystallography. Within both series of isomers the theoretical binding energies were in agreement with the enzymatic measurements, illustrating the power of the LIE method for the prediction of ligand affinities prior to synthesis. The structural models of the enzyme-inhibitor complexes obtained from the MD simulations provided a basis for interpretation of further structure-activity relationships. Hence, the affinity of a structurally similar ligand, but with a different P2/P2' substituent was examined using the same procedure. The predicted improvement in binding constant agreed well with experimental results.

UI MeSH Term Description Entries
D007189 Indans Aryl CYCLOPENTANES that are a reduced (protonated) form of INDENES. Indanones
D008353 Mannitol A diuretic and renal diagnostic aid related to sorbitol. It has little significant energy value as it is largely eliminated from the body before any metabolism can take place. It can be used to treat oliguria associated with kidney failure or other manifestations of inadequate renal function and has been used for determination of glomerular filtration rate. Mannitol is also commonly used as a research tool in cell biological studies, usually to control osmolarity. (L)-Mannitol,Osmitrol,Osmofundin
D008956 Models, Chemical Theoretical representations that simulate the behavior or activity of chemical processes or phenomena; includes the use of mathematical equations, computers, and other electronic equipment. Chemical Models,Chemical Model,Model, Chemical
D010963 Plasmodium falciparum A species of protozoa that is the causal agent of falciparum malaria (MALARIA, FALCIPARUM). It is most prevalent in the tropics and subtropics. Plasmodium falciparums,falciparums, Plasmodium
D011480 Protease Inhibitors Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES). Antiprotease,Endopeptidase Inhibitor,Endopeptidase Inhibitors,Peptidase Inhibitor,Peptidase Inhibitors,Peptide Hydrolase Inhibitor,Peptide Hydrolase Inhibitors,Peptide Peptidohydrolase Inhibitor,Peptide Peptidohydrolase Inhibitors,Protease Antagonist,Protease Antagonists,Antiproteases,Protease Inhibitor,Antagonist, Protease,Antagonists, Protease,Hydrolase Inhibitor, Peptide,Hydrolase Inhibitors, Peptide,Inhibitor, Endopeptidase,Inhibitor, Peptidase,Inhibitor, Peptide Hydrolase,Inhibitor, Peptide Peptidohydrolase,Inhibitor, Protease,Inhibitors, Endopeptidase,Inhibitors, Peptidase,Inhibitors, Peptide Hydrolase,Inhibitors, Peptide Peptidohydrolase,Inhibitors, Protease,Peptidohydrolase Inhibitor, Peptide,Peptidohydrolase Inhibitors, Peptide
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000962 Antimalarials Agents used in the treatment of malaria. They are usually classified on the basis of their action against plasmodia at different stages in their life cycle in the human. (From AMA, Drug Evaluations Annual, 1992, p1585) Anti-Malarial,Antimalarial,Antimalarial Agent,Antimalarial Drug,Anti-Malarials,Antimalarial Agents,Antimalarial Drugs,Agent, Antimalarial,Agents, Antimalarial,Anti Malarial,Anti Malarials,Drug, Antimalarial,Drugs, Antimalarial
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D013237 Stereoisomerism The phenomenon whereby compounds whose molecules have the same number and kind of atoms and the same atomic arrangement, but differ in their spatial relationships. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed) Molecular Stereochemistry,Stereoisomers,Stereochemistry, Molecular,Stereoisomer
D013816 Thermodynamics A rigorously mathematical analysis of energy relationships (heat, work, temperature, and equilibrium). It describes systems whose states are determined by thermal parameters, such as temperature, in addition to mechanical and electromagnetic parameters. (From Hawley's Condensed Chemical Dictionary, 12th ed) Thermodynamic

Related Publications

Karolina Ersmark, and Isabella Feierberg, and Sinisa Bjelic, and Johan Hultén, and Bertil Samuelsson, and Johan Aqvist, and Anders Hallberg
April 2003, Bioorganic & medicinal chemistry,
Karolina Ersmark, and Isabella Feierberg, and Sinisa Bjelic, and Johan Hultén, and Bertil Samuelsson, and Johan Aqvist, and Anders Hallberg
February 2003, Journal of medicinal chemistry,
Karolina Ersmark, and Isabella Feierberg, and Sinisa Bjelic, and Johan Hultén, and Bertil Samuelsson, and Johan Aqvist, and Anders Hallberg
January 2008, Bioorganicheskaia khimiia,
Karolina Ersmark, and Isabella Feierberg, and Sinisa Bjelic, and Johan Hultén, and Bertil Samuelsson, and Johan Aqvist, and Anders Hallberg
April 2014, Fitoterapia,
Karolina Ersmark, and Isabella Feierberg, and Sinisa Bjelic, and Johan Hultén, and Bertil Samuelsson, and Johan Aqvist, and Anders Hallberg
December 2015, Acta crystallographica. Section F, Structural biology communications,
Karolina Ersmark, and Isabella Feierberg, and Sinisa Bjelic, and Johan Hultén, and Bertil Samuelsson, and Johan Aqvist, and Anders Hallberg
June 2003, Current medicinal chemistry,
Karolina Ersmark, and Isabella Feierberg, and Sinisa Bjelic, and Johan Hultén, and Bertil Samuelsson, and Johan Aqvist, and Anders Hallberg
February 2016, Malaria journal,
Karolina Ersmark, and Isabella Feierberg, and Sinisa Bjelic, and Johan Hultén, and Bertil Samuelsson, and Johan Aqvist, and Anders Hallberg
September 1998, Bioorganic & medicinal chemistry letters,
Karolina Ersmark, and Isabella Feierberg, and Sinisa Bjelic, and Johan Hultén, and Bertil Samuelsson, and Johan Aqvist, and Anders Hallberg
October 2016, Biochimica et biophysica acta,
Karolina Ersmark, and Isabella Feierberg, and Sinisa Bjelic, and Johan Hultén, and Bertil Samuelsson, and Johan Aqvist, and Anders Hallberg
January 2010, Protein engineering, design & selection : PEDS,
Copied contents to your clipboard!